Multiple Myeloma

被引：59

作者：

Anderson, Kenneth C.

Alsina, Melissa ^{[1
]}

Bensinger, William

Biermann, J. Sybil ^{[2
]}

Chanan-Khan, Asher ^{[3
]}

Cohen, Adam D. ^{[4
]}

Devine, Steven ^{[5
,6
]}

Djulbegovic, Benjamin ^{[1
]}

Faber, Edward A., Jr. ^{[7
]}

Gasparetto, Cristina ^{[8
]}

Huff, Carol Ann ^{[9
]}

Kassim, Adetola ^{[10
]}

Medeiros, Bruno C. ^{[11
]}

Meredith, Ruby ^{[12
]}

Raje, Noopur ^{[13
]}

Schriber, Jeffrey ^{[14
]}

Singhal, Seema ^{[15
]}

Somlo, George

Stockerl-Goldstein, Keith ^{[16
,17
]}

Treon, Steven P.

Tricot, Guido ^{[18
]}

Weber, Donna M. ^{[19
]}

Yahalom, Joachim ^{[20
]}

Yunus, Furhan

机构：

[1] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[2] Univ Michigan Comprehens Canc Ctr, Ann Arbor, MI USA

[3] Roswell Pk Canc Inst, Buffalo, NY USA

[4] Fox Chase Canc Ctr, Philadelphia, PA USA

[5] Ohio State Univ Comprehens Canc Ctr James Canc Ho, Columbus, OH USA

[6] Solove Res Inst, Columbus, MS USA

[7] Nebraska Med Ctr, UNMC Eppley Canc Ctr, Omaha, NE USA

[8] Duke Canc Inst, Durham, NC USA

[9] Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Sidney, BC, Canada

[10] Vanderbilt Ingram Canc Ctr, Nashville, TN USA

[11] Stanford Canc Inst, Stanford, CA USA

[12] Univ Alabama Birmingham, Ctr Comprehens Canc, Birmingham, AL 35294 USA

[13] Massachusetts Gen Hosp Canc Ctr, Boston, MA USA

[14] City Hope Comprehens Canc Ctr, Duarte, CA USA

[15] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Evanston, IL 60208 USA

[16] Barnes Jewish Hosp, Siteman Canc Ctr, St Louis, MO USA

[17] Washington Univ Sch Med, Washington, DC USA

[18] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84112 USA

[19] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

[20] Mem Sloan Kettering Canc Ctr, New York, NY USA

来源：

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK | 2011年 / 9卷 / 10期

关键词：

NCCN Clinical Practice Guidelines; NCCN Guidelines; multiple myeloma; Waldenstrom's monoclonal protein; C-reactive protein; combination chemotherapy; stem cell transplant; primary amyloidosis; cytogenetics; proteasome inhibitor; immunomodulatory drugs; bisphosphonates; supportive therapies; novel therapies; STEM-CELL TRANSPLANTATION; HIGH-DOSE THERAPY; THALIDOMIDE PLUS DEXAMETHASONE; DONOR LYMPHOCYTE INFUSIONS; PEGYLATED LIPOSOMAL DOXORUBICIN; NEWLY-DIAGNOSED MYELOMA; HIGH RESPONSE RATES; LONG-TERM SURVIVAL; PHASE-III; INTERGROUPE-FRANCOPHONE;

D O I：

10.6004/jnccn.2011.0095

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：1146 / 1183

页数：38

共 200 条

[1] Thalidomide with or without dexamethasone for refractory or relapsing multiple myeloma [J].

Alexanian, R ;

Weber, D ;

Anagnostopoulos, A ;

Delasalle, K ;

Wang, M ;

Rankin, K .

SEMINARS IN HEMATOLOGY, 2003, 40 (04) :3-7

[2]

Alvares CL, 2006, HAEMATOLOGICA, V91, P141

[3] Thalidomide and dexamethasone for resistant multiple myeloma [J].

Anagnostopoulos, A ;

Weber, D ;

Rankin, K ;

Delasalle, K ;

Alexanian, R .

BRITISH JOURNAL OF HAEMATOLOGY, 2003, 121 (05) :768-771

[4]

Anderson KC, 2009, J CLIN ONCOL, V27

[5]

[Anonymous], BLOOD

[6]

[Anonymous], BLOOD

[7]

[Anonymous], HAEMATOLOGICA

[8]

[Anonymous], BLOOD

[9]

[Anonymous], 2010, BLOOD

[10]

[Anonymous], BLOOD

← 1 2 3 4 5 6 7 8 9 10 →